期刊名：Antibodies

期刊主页：https://www.mdpi.com/journal/antibodies

本期精选15篇抗体应用于癌症免疫治疗领域的文献，希望能为相关领域学者提供新的思路和参考，欢迎阅读。

1. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment

免疫细胞衔接器：推进癌症治疗的精准免疫疗法

https://www.mdpi.com/2073-4468/14/1/16

In, H.; Park, M.; Lee, H.; Han, K.H. Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies 2025, 14, 16.

2. TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth

利用特异性抗体阻断TLR2和TLR9可抑制炎症介导的胰腺癌细胞生长

https://www.mdpi.com/2073-4468/13/1/11

Ajay, A.K.; Gasser, M.; Hsiao, L.-L.; Böldicke, T.; Waaga-Gasser, A.M. TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth. Antibodies 2024, 13, 11.

3. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

抗MET抗体疗法在非小细胞肺癌中的应用：现状与未来方向

https://www.mdpi.com/2073-4468/13/4/88

Wang, K.; Hsu, R. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies 2024, 13, 88.

4. Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers

阿那曲唑和他莫昔芬对Luminal A型和Luminal B型乳腺癌中IgG糖组组成动态的影响

https://www.mdpi.com/2073-4468/13/1/9

Rapcan, B.; Fancovic, M.; Pribic, T.; Kirac, I.; Gace, M.; Vuckovic, F.; Lauc, G. Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers. Antibodies 2024, 13, 9.

5. Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1

平衡同时靶向 EGFR 和 PD-L1 的二合一抗体的亲和力和肿瘤细胞结合能力

https://www.mdpi.com/2073-4468/13/2/36

Harwardt, J.; Geyer, F.K.; Schoenfeld, K.; Baumstark, D.; Molkenthin, V.; Kolmar, H. Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1. Antibodies 2024, 13, 36.

6. Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer

靶向癌症新抗原：乳腺癌治疗的可能性和机遇

https://www.mdpi.com/2073-4468/13/2/46

Chaudhry, Z.; Boyadzhyan, A.; Sasaninia, K.; Rai, V. Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer. Antibodies 2024, 13, 46.

7. Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer

利用抗体染料偶联物靶向CD44和EpCAM进行前列腺癌光免疫治疗

https://www.mdpi.com/2073-4468/14/1/5

Wolf, I.; Schultze-Seemann, S.; Gratzke, C.; Wolf, P. Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer. Antibodies 2025, 14, 5.

8. Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy

开发靶向SIRPα和PLA2G7的全人源抗体用于癌症治疗

https://www.mdpi.com/2073-4468/14/1/21

Shin, S.; Baek, D.-S.; Mellors, J.W.; Dimitrov, D.S.; Li, W. Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy. Antibodies 2025, 14, 21.

9. Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy

鉴定一种靶向间变性淋巴瘤激酶（ALK）的全人源VH结构域抗体，并应用于ALK阳性实体瘤免疫治疗

https://www.mdpi.com/2073-4468/13/2/39

Chen, C.; Sun, Z.; Wang, Z.; Shin, S.; Berrios, A.; Mellors, J.W.; Dimitrov, D.S.; Li, W. Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy. Antibodies 2024, 13, 39.

10. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model

177Lu抗血管生成放射免疫疗法靶向胃癌模型中的ATP合酶

https://www.mdpi.com/2073-4468/13/3/51

Park, B.-N.; An, Y.-S.; Kim, S.-M.; Lee, S.-J.; Park, Y.-J.; Yoon, J.-K. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model. Antibodies 2024, 13, 51.

11. Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions

预防性癌症疫苗诱导产生的抗MUC1抗体具有多种效应功能

https://www.mdpi.com/2073-4468/13/4/85

McKeague, M.L.; Lohmueller, J.; Dracz, M.T.; Saadallah, N.; Ricci, E.D.; Beckwith, D.M.; Ayyalasomayajula, R.; Cudic, M.; Finn, O.J. Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions. Antibodies 2024, 13, 85.

12. Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies

基于片段的免疫细胞衔接抗体在癌症、传染病和自身免疫性疾病治疗中的应用：来自临床和转化研究的经验和见解

https://www.mdpi.com/2073-4468/14/3/52

Yang, G.; Massumi, M. Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies. Antibodies 2025, 14, 52.

13. A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide

一种新型四价双特异性免疫细胞结合剂可激活自然杀伤细胞杀死癌细胞，且不引起同胞相残

https://www.mdpi.com/2073-4468/13/3/75

Yang, G.; Nikkhoi, S.K.; Owji, H.; Li, G.; Massumi, M.; Cervelli, J.; Vandavasi, V.G.; Hatefi, A. A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide. Antibodies 2024, 13, 75.

14. Comparative Evaluation of Three Primary Antibody Clones for p16 Immunohistochemistry in Gynecologic Tumors

三种用于妇科肿瘤p16免疫组化检测的原代抗体克隆的比较评价

https://www.mdpi.com/2073-4468/14/3/77

Yoshida, H.; Sugitani, A.; Kobayashi-Kato, M.; Uno, M.; Ishikawa, M. Comparative Evaluation of Three Primary Antibody Clones for p16 Immunohistochemistry in Gynecologic Tumors. Antibodies 2025, 14, 77.

15. Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL

利用噬菌体展示技术生成针对肿瘤相关抗原AXL的pH依赖性抗体

https://www.mdpi.com/2073-4468/14/4/83

Mangeat, T.; Mairaville, C.; Chentouf, M.; Neiveyans, M.; Pugnière, M.; Ngo, G.; Denis, V.; Catherine, C.; Pichard, A.; Deshayes, E.; et al. Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL. Antibodies 2025, 14, 83.

期刊简介

主编：Arne Skerra, Technical University of Munich, Germany

期刊主题涵盖抗体和体液免疫反应、抗体的发现、产生和选择、抗体结构和功能、抗体工程、结合物和融合蛋白、生物医学研究和治疗中的抗体。

2024 Impact Factor: 2.7

2024 CiteScore: 4.5

Time to First Decision: 19.5 Days

Acceptance to Publication: 5.7 Days